Work

CLL Cells From Subjects Treated with Rituximab and Alemtuzumab Can Lose Target Antigen and Develop Resistance to Mab-Mediated Complement Dependent Cytotoxicity

Year: 2010

Type: article

Source: Blood

DOI: 10.1182/blood.v116.21.3585.3585

Authors: Ronald P Taylor, Clive S. Zent, Paul V Beum, Margaret A Lindorfer, George Weiner

Institutions: University of Virginia, Mayo Clinic, University of Iowa, University of Iowa Holden Comprehensive Cancer Center

Language: English

Topic: Chronic Lymphocytic Leukemia Research

Subfield: Genetics

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2557644565

FWCI:

Cites:

Cited by:

Related to: 10